Skip to main content
SpringerLink
Log in

NGAL and AKI: the end of a myth?

  • Editorial
  • Published:
Intensive Care Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abbreviations

AKI:

Acute kidney injury

NGAL:

Neutrophil gelatinase-associated lipocalin

RRT:

Renal replacement therapy

References

  1. Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N (1993) Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 268:10425–10432

    PubMed  CAS  Google Scholar 

  2. Schmidt-Ott KM, Mori K, Li JY, Kalandadze A, Cohen DJ, Devarajan P, Barasch J (2007) Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 18:407–413

    Article  PubMed  CAS  Google Scholar 

  3. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P (2003) Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 14:2534–2543

    Article  PubMed  CAS  Google Scholar 

  4. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Shao M, Bean J, Mori K, Barasch J, Devarajan P (2005) Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 365:1231–1238

    Article  PubMed  CAS  Google Scholar 

  5. Mishra J, Ma Q, Kelly C, Mitsnefes M, Mori K, Barasch J, Devarajan P (2006) Kidney NGAL is a novel early marker of acute injury following transplantation. Pediatr Nephrol 21:856–863

    Article  PubMed  Google Scholar 

  6. de Geus HR, Bakker J, Lesaffre EM, le Noble JL (2011) Neutrophil gelatinase-associated lipocalin at ICU admission predicts for acute kidney injury in adult patients. Am J Respir Crit Care Med 183:907–914

    Article  PubMed  Google Scholar 

  7. Nickolas TL, O’Rourke MJ, Yang J, Sise ME, Canetta PA, Barasch N, Buchen C, Khan F, Mori K, Giglio J, Devarajan P, Barasch J (2008) Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. Ann Intern Med 148:810–819

    Article  PubMed  Google Scholar 

  8. Hjortrup PB, Haase N, Wetterslev M, Perner A (2013) Clinical review: predictive value of neutrophil gelatinase-associated lipocalin for acute kidney injury in intensive care patients. Crit Care 17:211

    Article  PubMed  Google Scholar 

  9. Martensson J, Bell M, Oldner A, Xu S, Venge P, Martling CR (2010) Neutrophil gelatinase-associated lipocalin in adult septic patients with and without acute kidney injury. Intensive Care Med 36:1333–1340

    Article  PubMed  CAS  Google Scholar 

  10. Eagan TM, Damas JK, Ueland T, Voll-Aanerud M, Mollnes TE, Hardie JA, Bakke PS, Aukrust P (2010) Neutrophil gelatinase-associated lipocalin: a biomarker in COPD. Chest 138:888–895

    Article  PubMed  Google Scholar 

  11. Maisel AS, Mueller C, Fitzgerald R, Brikhan R, Hiestand BC, Iqbal N, Clopton P, van Veldhuisen DJ (2011) Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic peptide in acutely decompensated heart failure (GALLANT) trial. Eur J Heart Fail 13:846–851

    Article  PubMed  CAS  Google Scholar 

  12. Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A (2009) Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 54:1012–1024

    Article  PubMed  CAS  Google Scholar 

  13. McIlroy DR, Wagener G, Lee HT (2010) Neutrophil gelatinase-associated lipocalin and acute kidney injury after cardiac surgery: the effect of baseline renal function on diagnostic performance. Clin J Am Soc Nephrol 5:211–219

    Article  PubMed  CAS  Google Scholar 

  14. Glassford NJ, Schneider AG, Xu S, Eastwood GN, Young HPL, Venge P, Bellomo R (2013) The nature and discriminatory value of urinary neutrophil gelatinase-associated lipocalin in critically ill patients at risk of acute kidney injury. Intensive Care Med. doi:10.1007/s00134-013-3040-7

    Google Scholar 

  15. Cai L, Borowiec J, Xu S, Han W, Venge P (2009) Assays of urine levels of HNL/NGAL in patients undergoing cardiac surgery and the impact of antibody configuration on their clinical performances. Clin Chim Acta 403:121–125

    Article  PubMed  CAS  Google Scholar 

  16. Cai L, Rubin J, Han W, Venge P, Xu S (2010) The origin of multiple molecular forms in urine of HNL/NGAL. Clin J Am Soc Nephrol 5:2229–2235

    Article  PubMed  CAS  Google Scholar 

  17. Martensson J, Xu S, Bell M, Martling CR, Venge P (2012) Immunoassays distinguishing between HNL/NGAL released in urine from kidney epithelial cells and neutrophils. Clin Chim Acta 413:1661–1667

    Article  PubMed  CAS  Google Scholar 

  18. Legrand M, Collet C, Gayat E, Henao J, Giraudeaux V, Mateo J, Launay JM, Payen D (2013) Accuracy of urine NGAL commercial assays in critically ill patients. Intensive Care Med 39:541–542

    Article  PubMed  Google Scholar 

  19. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A (2007) Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 11:R31

    Article  PubMed  Google Scholar 

  20. Krawczeski CD, Goldstein SL, Woo JG, Wang Y, Piyaphanee N, Ma Q, Bennett M, Devarajan P (2011) Temporal relationship and predictive value of urinary acute kidney injury biomarkers after pediatric cardiopulmonary bypass. J Am Coll Cardiol 58:2301–2309

    Article  PubMed  CAS  Google Scholar 

Download references

Conflicts of interest

MD report no conflict of interest. ML received lectures fees from Alere. MJ has received speaker′s honoraria or consulting fees from Baxter, Gambro, Fresenius, CLS Behring, Braun, AM Pharma and Sanofi.

Author information

Authors and Affiliations

  1. Department of Anesthesiology and Critical Care and Burn Center, Hôpitaux Universitaires St-Louis-Lariboisièere, APHP, Paris, France

    Matthieu Legrand

  2. UMR S942 Inserm, Hospital Lariboisiere, Paris, France

    Matthieu Legrand

  3. University Paris 7, Diderot, Paris, France

    Matthieu Legrand

  4. Medical ICU, Saint-Etienne University Hospital, Avenue Albert Raymond, Saint-Priest en Jarez, 42270, France

    Michael Darmon

  5. Jacques Lisfranc Medical School, Saint-Etienne University, Saint-Etienne, France

    Michael Darmon

  6. Medical Intensive Care and Emergency Unit, Department of Internal Medicine, Medical University Innsbruck, Anichstr. 35, 6020, Innsbruck, Austria

    Michael Joannidis

Authors
  1. Matthieu Legrand
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Darmon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Joannidis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Joannidis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Legrand, M., Darmon, M. & Joannidis, M. NGAL and AKI: the end of a myth?. Intensive Care Med 39, 1861–1863 (2013). https://doi.org/10.1007/s00134-013-3061-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00134-013-3061-2

Search

Navigation